Global Phenylpropanolamine (PPA) Market – Industry Trends and Forecast to 2030

Analyse du marché et de la taille de la phénylpropanolamine (PPA)

Le PPA ou phénylpropanolamine est une substance synthétique qui supprime la faim et agit comme un décongestionnant. Le marché du phénylpropanolamine (PPA) va commencer à décoller au cours de la période de projection ci-dessus en raison de plusieurs changements provoqués par l'augmentation du revenu disponible des clients dans les économies émergentes et l'utilisation de ce médicament dans diverses combinaisons.                   

Selon les analyses de Data Bridge Market Research, le marché de la phénylpropanolamine devrait connaître un TCAC de 5,8 % au cours de la période de prévision de 2023 à 2030. Les médicaments en vente libre dominent le segment des types de médicaments du marché de la phénylpropanolamine en raison de la prévalence croissante de l'utilisation de médicaments. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché de la phénylpropanolamine (PPA)

Définition du marché

Le PPA, ou phénylpropanolamine, est une substance synthétique qui supprime la faim et agit comme un décongestionnant. Il fait partie du groupe de médicaments appelés amines sympathomimétiques, qui imitent les actions du système nerveux sympathique. Le PPA était fréquemment utilisé comme composant dans les médicaments en vente libre contre la sinusite, la congestion nasale et la perte de poids.

Dynamique du marché de la phénylpropanolamine (PPA)

Conducteurs

• Sensibilisation accrue à la phénylpropanolamine

Pour des soins appropriés aux patients, il est essentiel de former le personnel de santé aux problèmes de sécurité liés au PPA. La diffusion de connaissances actualisées sur le PPA et ses alternatives est facilitée par des directives cliniques, des programmes de formation médicale continue et des discussions au sein de la communauté médicale. Pour encourager une utilisation sûre des médicaments, il est essentiel d'informer les clients des dangers et des effets indésirables possibles du PPA. Les connaissances des experts de la santé, les étiquettes des produits et les initiatives de sensibilisation des consommateurs peuvent tous aider les gens à prendre des décisions éclairées en matière de santé. Ainsi, une sensibilisation accrue à la phénylpropanolamine agit comme un moteur de croissance du marché.

• Accroître les activités de recherche

Les entreprises pharmaceutiques ou les chercheurs pourraient avoir l'occasion de se pencher sur la création de décongestionnants ou de coupe-faim plus sûrs et plus puissants. Il existe encore un marché pour ces produits ; l'innovation dans ce domaine pourrait apaiser les inquiétudes de PPA en matière de sécurité.

• Progrès technologiques croissants

Les progrès réalisés dans le domaine de la modélisation informatique, de la biologie moléculaire et du criblage à haut débit peuvent contribuer au développement de nouveaux médicaments. Ces progrès pourraient éventuellement conduire à la découverte de décongestionnants ou de coupe-faim plus sûrs et plus puissants que le PPA. Désormais, les avancées et innovations technologiques croissantes à travers le monde démontrent la croissance future du marché.

Opportunités

• Utilisation croissante de produits combinés

En médecine, la phénylpropanolamine est souvent utilisée en association avec d’autres substances actives. Il est possible de créer des médicaments qui répondent à plusieurs symptômes ou problèmes de santé, par exemple en combinant des caractéristiques décongestionnantes avec d’autres avantages thérapeutiques. Cela pourrait répondre aux préférences et aux besoins changeants des consommateurs. Cela crée une opportunité majeure pour le marché.

• Augmentation des dépenses de santé

The expense of money a country uses on its healthcare and its growth rate over time is inclined by a wide variety of economic and social factors, including the financing arrangements and structure of the organization of the health system. Healthcare expenditure has increased across developed countries and emerging economies as people's disposable income rises. Hence, colossal healthcare expenditure is a favorable factor for market growth.

• Increasing demand for personalized medicine

Personalized medicine has been made possible by developing technology like genetic testing, biomarker identification, and data analytics. This method customizes medical care to each person's specific traits and requirements. Although not directly connected to PPA, personalized medicine may influence the creation of upcoming drugs and treatment plans. These affirmative factors enhance the opportunity for market growth.

Challenges/ Restraints

• Regulatory guidelines

Governmental constraints on regulatory freedom have greatly impacted the world PPA market. Many nations have outright outlawed PPA use or imposed onerous restrictions on its sale and distribution. These regulatory efforts restrict the use of PPA-based goods by reducing their availability and market potential. Thus, regulatory guidelines for phenylpropanolamine may hamper the market's future growth.

• Safety concerns

Safety issues related to its use have been the main barrier to the market for PPA. It has been related in studies to a higher risk of stroke, particularly in women. As a result, regulatory bodies in numerous nations have taken steps to limit or forbid the sale of drugs that contain PPA. The demand for PPA has decreased, and consumers are switching to other decongestants and appetite suppressants due to safety concerns.  Thus, safety concerns for phenylpropanolamine may hamper the market growth.

• Availability of alternatives

In addition, the market expansion has been constrained by the advent of safer substitutes. Pharmacies and academics have created and marketed substitute decongestants and appetite suppressants with superior safety profiles as worries about PPA's safety have grown. There is now less demand for PPA because more patients and healthcare professionals are switching to these safer substitutes.

• The cost associated with biomarker discovery

Consumer choices and awareness significantly shape the market dynamics. The difficulty is raising customer awareness of the safety issues around PPA and encouraging safer substitutes. Effective marketing tactics and awareness-raising efforts are needed to adapt to changing customer preferences and raise public awareness. Thus, changing consumer preferences and awareness regarding phenylpropanolamine may challenge the market's growth.

This phenylpropanolamine (PPA) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the phenylpropanolamine (PPA) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Phenylpropanolamine (PPA) Market Scope

The phenylpropanolamine (PPA) market is segmented on the basis of indication, chemistry, application, drug type, population type, dosage form, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Indication

• Colds
• Hay fever
• Upper respiratory allergies
• Sinusitis
• Others

Application

• Human
• Veterinary

Drug Type

• Over the Counter
• Prescription

Population Type

• Children
• Adults

Dosage Form

• Solid dosage form
• Tablets
• Capsules
• Liquid dosage form
• Others

End User

• Hospitals
• Specialty Clinics
• Home healthcare
• Others

Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
• Others

Phenylpropanolamine (PPA) Market Regional Analysis/Insights

The phenylpropanolamine (PPA) market is analysed and market size insights and trends are provided by indication, chemistry, application, drug type, population type, dosage form, end user and distribution channel as referenced above.

The countries covered in the phenylpropanolamine (PPA) market report are U.S., Canada, Mexico, Brazil, Argentina, Peru, rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, rest of Middle East and Africa.

Asia-Pacific governs the market industry due to the drug's availability in OTC and prescription and rising disposable income. At the same time, Europe is anticipated to expand at the leading germination pace from 2023 to 2030 due to the presence of an isomeric form of this drug in the European market.

The country section of the phenylpropanolamine (PPA) market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The phenylpropanolamine (PPA) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Phenylpropanolamine (PPA) Market Share Analysis

The phenylpropanolamine (PPA) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to phenylpropanolamine (PPA) market.

Some of the major players operating in the phenylpropanolamine (PPA) market are:

• RIEMSER Pharma GmbH (Germany)
• Abbott (U.S.)
• Helicon (Canada)
• EIPICO (Egypt)
• Schazoo Pharmaceuticals Pvt. Ltd (Pakistan)
• GlaxoSmithKline plc (U.K.)
• Roemmers SAICF (Argentina)
• Taj Pharmaceuticals Ltd. (India)
• Cipla Inc. (India)
• Medline Industries, Inc. (U.S.)
• Sanofi (France)
• Tempo Scan Pacific Tbk Carinopharm (Indonesia)
• IBL HealthCare (India)
• PT. Gracia Pharmindo (Indonesia) 

SKU-60010